Immunotherapy

Researchers report that a single injection of a modified herpes virus draws immune cells deep into glioblastoma tumors, leading to longer survival in a clinical trial. The therapy, tested on 41 patients with recurrent brain cancer, activates T cells that persist and attack cancer cells. Findings were published in Cell.

16. maaliskuuta 2026 Raportoinut AI

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

Scientists at Northwestern Medicine have developed an antibody that counters pancreatic cancer's sugar-based disguise, enabling the immune system to attack tumors more effectively. In mouse studies, the therapy slowed tumor growth by restoring immune activity. The team is preparing the antibody for human trials.

11. tammikuuta 2026 Raportoinut AI

Researchers at KAIST have developed an injection that transforms immune cells within tumors into active cancer-killing agents, bypassing the need for complex lab procedures. The method uses lipid nanoparticles to deliver instructions directly to macrophages, enabling them to recognize and attack cancer cells while boosting broader immune responses. In animal tests, the approach significantly slowed tumor growth in melanoma models.

Researchers at Washington University School of Medicine in St. Louis, working with scientists at Northwestern University, have developed a noninvasive nasal nanotherapy that activates the immune system to attack aggressive brain tumors in mice. By delivering spherical nucleic acids that trigger the STING immune pathway directly from the nose to the brain, the approach eliminated glioblastoma tumors in mouse models when combined with drugs that boost T-cell activity, according to a study in the Proceedings of the National Academy of Sciences.

21. marraskuuta 2025 Raportoinut AI Faktatarkistettu

Researchers at the Institut Pasteur and Inserm have developed a triple-drug strategy that induces necroptosis in malignant B cells, triggering a strong anti-tumor immune response in preclinical models of leukemia. By reprogramming how cancer cells die, the approach enabled complete leukemia elimination in animals and may offer a new avenue for treating B cell-related blood cancers, according to findings published in Science Advances.